NXTC NextCure
Price Chart
Executive Summary
NextCure announced that Phase 1 data for SIM0505, an investigational antibody-drug conjugate targeting CDH6 in solid tumors, will be presented at ASCO 2026. The poster presentation represents a clinical milestone for the program but does not include new efficacy or safety data.
Actionable Insight
Monitor the ASCO poster for signs of clinical activity and tolerability in solid tumors, particularly in platinum-resistant ovarian cancer, which could influence future development plans and partnership interest. Lack of data in this release limits immediate trading implications.
Key Facts
- Phase 1 data for SIM0505 to be presented at ASCO 2026 in a poster session on June 1, 2026.
- SIM0505 is an anti-CDH6 antibody-drug conjugate with a proprietary TOPOi payload, being evaluated in advanced solid tumors including platinum-resistant ovarian cancer.
- NextCure holds global rights to SIM0505 except in China, Hong Kong, Macau, and Taiwan, which are retained by Simcere Zaiming.
- No clinical results or financial figures were disclosed in the press release.
Financial Impact
No direct financial impact disclosed; presentation may provide clinical validation and de-risk the asset modestly.
Risk Factors
- Phase 1 data may show limited efficacy or safety concerns, limiting further development.
- NextCure remains pre-revenue with a history of losses and dependence on external financing.
Market Snapshot
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3278150 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 1, 2026
9d ago
|
8-K
| $3.38 $2.95 | ▼ −12.72% | ▼ −9.97% | $2.21 (−34.62%) |
|
Jun 1, 2026
9d ago
|
Press Release
| $3.38 $2.95 | ▼ −12.72% | ▼ −9.97% | $2.21 (−34.62%) |
|
May 7, 2026
4w ago
|
8-K
| $9.76 $10.25 | ▲ +5.02% | ▲ +3.56% | $2.21 (−77.36%) |
|
May 4, 2026
5w ago
|
Press Release
| $8.92 $9.78 | ▲ +9.64% | ▲ +6.71% | $2.21 (−75.22%) |
|
Apr 24, 2026
6w ago
|
DEFA14A
| $9.62 $8.92 | ▼ −7.28% | ▼ −7.68% | $2.21 (−77.03%) |
|
Apr 21, 2026
7w ago
|
Press Release
| $10.97 $9.25 | ▼ −15.68% | ▼ −16.76% | $2.21 (−79.85%) |
|
Mar 5, 2026
13w ago
|
8-K
| $12.39 $12.68 | ▲ +2.34% | ▲ +3.87% | $2.21 (−82.16%) |
|
Mar 5, 2026
13w ago
|
Press Release
| $12.39 $12.68 | ▲ +2.34% | ▲ +3.87% | $2.21 (−82.16%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access